IDH1 mutation of gliomas with long-term survival analysis

Myung,Jae  Kyung; Cho,Hwa  Jin; Park,Chul-Kee; Kim,Seung-Ki; Phi,Ji  Hoon; Park,Sung-Hye

doi:10.3892/or.2012.1994

IDH1 mutation of gliomas with long-term survival analysis

Authors:
- Jae Kyung Myung
- Hwa Jin Cho
- Chul-Kee Park
- Seung-Ki Kim
- Ji Hoon Phi
- Sung-Hye Park
View Affiliations

Affiliations: Department of Pathology, Seoul National University Hospital, College of Medicine, Seoul, Republic of Korea, Department of Neurosurgery, Seoul National University, College of Medicine, Seoul, Republic of Korea, Department of Pediatric Neurosurgery, Seoul National University Children's Hospital, College of Medicine, Seoul, Republic of Korea
Published online on: August 24, 2012 https://doi.org/10.3892/or.2012.1994
Pages: 1639-1644

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A recurrent mutation affecting codon 132 of the isocitrate dehydrogenase 1 (IDH1) gene has been found in ~5% of primary glioblastomas (GBMs), but in >70% of secondary GBMs or oligodendroglial and astrocytic tumors. We investigated IDH1 mutations in a series of 134 brain tumors to determine the prevalence and prognostic impact of IDH1 mutations. We also examined the correlations among histology, p53 and PTEN immunoexpression, MGMT methylation status, 1p 19q co-deletion and EGFR gene amplification. The 134 brain tumors included 41 low-grade oligodendrogliomas (LOs), 47 anaplastic oligodendrogliomas (AOs) and 46 primary GBMs. Data showed that 53.7% (72/134) of cases showed mutations affecting codon 132 of IDH1, including 73.2% of LOs, 82.9% of AOs and three primary GBMs (6.5%). All IDH1 mutations were Arg132His. In a survival analysis, patients with IDH1 mutations had better survival compared to those with wild-type IDH1 (p<0.05) in LOs and AOs, but not in primary GBMs (p=0.587). In addition, in patients with both IDH1 mutation and MGMT methylation, p53 overexpression was a significant poor prognostic factor both in LOs and AOs. However, IDH1 mutation was not correlated with common genetic profiles that affect patient prognosis, including MGMT methylation, 1p 19q co-deletion, PTEN loss and EGFR amplification in LOs, AOs and GBMs. From our results, IDH1 mutation was an independent positive prognostic factor in LOs and AOs, especially in the absence of p53 overexpression.

View Figures

View References

1	Parsons DW, Jones S, Zhang X, et al: An integrated genomic analysis of human glioblastoma multiforme. Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI
2	Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C and von Deimling A: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 116:597–602. 2008. View Article : Google Scholar : PubMed/NCBI
3	Bleeker FE, Atai NA, Lamba S, et al: The prognostic IDH1 (R132) mutation is associated with reduced NADP (+)-dependent IDH activity in glioblastoma. Acta Neuropathol. 119:487–494. 2010.
4	Bujko M, Kober P, Matyja E, et al: Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients. Mol Diagn Ther. 14:163–169. 2010. View Article : Google Scholar : PubMed/NCBI
5	Capper D, Weissert S, Balss J, et al: Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 20:245–254. 2010. View Article : Google Scholar : PubMed/NCBI
6	Dang L, White DW, Gross S, et al: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 462:739–744. 2009. View Article : Google Scholar : PubMed/NCBI
7	De Carli E, Wang X and Puget S: IDH1 and IDH2 mutations in gliomas. N Engl J Med. 360:2248author reply 2249. 2009.
8	Dubbink HJ, Taal W, van Marion R, et al: IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology. 73:1792–1795. 2009. View Article : Google Scholar : PubMed/NCBI
9	Ducray F, Marie Y and Sanson M: IDH1 and IDH2 mutations in gliomas. N Engl J Med. 360:248author reply 2249. 2009.
10	Ferroli P, Acerbi F and Finocchiaro G: From standard treatment to personalized medicine: role of IDH1 mutations in low-grade glioma evolution and treatment. World Neurosurg. 73:234–236. 2010. View Article : Google Scholar : PubMed/NCBI
11	Frezza C, Tennant DA and Gottlieb E: IDH1 mutations in gliomas: when an enzyme loses its grip. Cancer Cell. 17:7–9. 2010. View Article : Google Scholar : PubMed/NCBI
12	Gravendeel LA, Kloosterhof NK, Bralten LB, et al: Segregation of non-p. R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum Mutat. 31:E1186–E1199. 2010. View Article : Google Scholar : PubMed/NCBI
13	Hartmann C, Meyer J, Balss J, et al: Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 118:469–474. 2009. View Article : Google Scholar : PubMed/NCBI
14	Hayden JT, Fruhwald MC, Hasselblatt M, Ellison DW, Bailey S and Clifford SC: Frequent IDH1 mutations in supratentorial primitive neuroectodermal tumors (sPNET) of adults but not children. Cell Cycle. 8:1806–1807. 2009. View Article : Google Scholar : PubMed/NCBI
15	Horbinski C, Kelly L, Nikiforov YE, Durso MB and Nikiforova MN: Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. TJ Mol Diagn. 12:487–492. 2010. View Article : Google Scholar : PubMed/NCBI
16	Horbinski C, Kofler J, Kelly LM, Murdoch GH and Nikiforova MN: Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol. 68:1319–1325. 2009. View Article : Google Scholar
17	Houillier C, Wang X, Kaloshi G, et al: IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology. 75:1560–1566. 2010. View Article : Google Scholar : PubMed/NCBI
18	Ichimura K, Pearson DM, Kocialkowski S, et al: IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neurooncology. 11:341–347. 2009.PubMed/NCBI
19	Kang MR, Kim MS, Oh JE, et al: Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer. 125:353–355. 2009. View Article : Google Scholar : PubMed/NCBI
20	Komotar RJ, Starke RM, Sisti MB and Connolly ES: IDH1 and IDH2 mutations in gliomas and the associated induction of hypoxia-inducible factor and production of 2-hydroxyglutarate. Neurosurgery. 66:N20–N21. 2010. View Article : Google Scholar : PubMed/NCBI
21	Larsen CJ: Mutations of IDH1 and 2 genes: a molecular diagnosis of low-grade gliomas. Bull Cancer. 96:641–642. 2009.(In French).
22	Nobusawa S, Watanabe T, Kleihues P and Ohgaki H: IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 15:6002–6007. 2009. View Article : Google Scholar : PubMed/NCBI
23	Sanson M, Marie Y, Paris S, et al: Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 27:4150–4154. 2009. View Article : Google Scholar : PubMed/NCBI
24	Sonoda Y, Kumabe T, Nakamura T, et al: Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci. 100:1996–1998. 2009. View Article : Google Scholar : PubMed/NCBI
25	Uno M, Oba-Shinjo SM, Silva R, et al: IDH1 mutations in a Brazilian series of glioblastoma. Clinics (Sao Paulo). 66:163–165. 2011. View Article : Google Scholar : PubMed/NCBI
26	Van den Bent MJ, Dubbink HJ, Marie Y, et al: IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 16:1597–1604. 2010.PubMed/NCBI
27	Watanabe T, Nobusawa S, Kleihues P and Ohgaki H: IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 174:1149–1153. 2009. View Article : Google Scholar : PubMed/NCBI
28	Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med. 360:765–773. 2009. View Article : Google Scholar : PubMed/NCBI
29	Zhao S, Lin Y, Xu W, et al: Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 324:261–265. 2009. View Article : Google Scholar : PubMed/NCBI
30	Thol F, Weissinger EM, Krauter J, et al: IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica. 95:1668–1674. 2010. View Article : Google Scholar : PubMed/NCBI
31	Murugan AK, Bojdani E and Xing M: Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun. 393:555–559. 2010. View Article : Google Scholar : PubMed/NCBI
32	Oki K, Takita J, Hiwatari M, et al: IDH1 and IDH2 mutations are rare in pediatric myeloid malignancies. Leukemia. 25:382–384. 2011. View Article : Google Scholar : PubMed/NCBI
33	Schnittger S, Haferlach C, Ulke M, Alpermann T, Kern W and Haferlach T: IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood. 116:5486–5496. 2010.
34	Weller M, Felsberg J, Hartmann C, et al: Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. 27:5743–5750. 2009. View Article : Google Scholar
35	Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK and Kim WH: EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology. 52:738–746. 2008. View Article : Google Scholar : PubMed/NCBI
36	Jeon YK, Park K, Park CK, Paek SH, Jung HW and Park SH: Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization. Neuropathology. 27:10–20. 2007. View Article : Google Scholar : PubMed/NCBI
37	Park CK, Park SH, Lee SH, et al: Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin. Neuropathology. 29:443–449. 2009. View Article : Google Scholar : PubMed/NCBI